

Trials and Trial Regimen Updates

Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens. For questions about these trials and regimens, please contact SCRI.DLEMRAlysts@scri.com.

Study Number	New Build Completed		
	X	X	Notes for New Build
24050	X		USOR 24050 Bridging Therapy (Optional) Dexamethasone or Corticosteroid Q7D USOR 24050 KITE-363 D0-7 USOR 24050 KITE-753 D0-7 USOR 24050 Lymphodepletion Cyclophosphamide D-5, -4, -3 + Fludarabine D-5, -4, -3

Study Number	Updated Reference Information				
	X	X	Other Changes		
				Updated Drug Service Order Information	
				Updated Regimen Instructions	
22083	X	X	Daily dosing days for Sch A changed to D2-8 (from D1-8) Administration instructions updated for Sch A&B Change in amount of “recon soln units” from 0 to 3 million in InvestMedDispense/ InvestMedSelfAdmin instructions		
23078	X		Premedication/post-med info added for IRR management. Handling of study drug changed to align with pharmacy instructions Sec 9.1.2		
22331	X				

Study Number	Updated Reference Information		
	Updated Drug Service Order Information		
	Updated Regimen Instructions		
	Other Changes		
21353	X		